STATE OF THE ART PAPER
Inducing apolipoprotein A-I synthesis to reduce cardiovascular risk: from ASSERT to SUSTAIN and beyond
 
More details
Hide details
Submission date: 2015-08-27
Final revision date: 2015-11-17
Acceptance date: 2015-11-17
Online publication date: 2016-10-24
Publication date: 2016-10-20
 
Arch Med Sci 2016;12(6):1302–1307
 
KEYWORDS
TOPICS
ABSTRACT
Increasing attention has focused on efforts to promote the biological activities of high-density lipoproteins (HDL) in order to reduce cardiovascular risk. Targeting apolipoprotein A-I (apoA-I), the major protein carried on HDL particles, represents an attractive approach to promoting HDL by virtue of its ability to increase endogenous synthesis of functional HDL particles. A number of pharmacological strategies that target apoA-I, including upregulation of its production with the bromodomain and extraterminal (BET) protein inhibitor RVX-208, development of short peptide sequences that mimic its action, and administration as a component of reconstituted HDL particles, have undergone clinical development. The impact of these approaches on cardiovascular biomarkers will be reviewed.
eISSN:1896-9151
ISSN:1734-1922